CalciMedica (CALC) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T20:35:52.693Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:35:52.693Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 1.49
Unrounded diluted TTM EPS · period ending 2026-06-30: -6.95

FMP input reference: e9e072c721023a8f5b36c3f5b81ac18026d6678c99aa2a087bce1e48ab153e53

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

CALC PE Ratio Metrics

PE RATIO

N/A

CALC Competitors' PE Ratio

CALC

CalciMedica, Inc.

Current

Market Cap

$4.69M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMNN

Imunon, Inc.

vs CALC

Market Cap

$4.71M

PE Ratio

N/A

TTM Avg

1.64

3Y Avg

1.64

5Y Avg

1.64

BGMS

Bio Green Med Solution, Inc.

vs CALC

Market Cap

$4.72M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRMA

Dermata Therapeutics, Inc.

vs CALC

Market Cap

$4.55M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMCB

PharmaCyte Biotech, Inc.

vs CALC

Market Cap

$4.53M

PE Ratio

N/A

TTM Avg

1.25

3Y Avg

1.25

5Y Avg

1.25

XBIO

Xenetic Biosciences, Inc.

vs CALC

Market Cap

$4.86M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LIMN

Liminatus Pharma, Inc. Class A Common Stock

vs CALC

Market Cap

$4.97M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLGN

CollPlant Biotechnologies Ltd.

vs CALC

Market Cap

$4.40M

PE Ratio

N/A

TTM Avg

79.42

3Y Avg

79.42

5Y Avg

79.42

AIDX

20/20 Biolabs Inc.

vs CALC

Market Cap

$4.32M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LNAI

Lunai Bioworks Inc.

vs CALC

Market Cap

$5.12M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
CalciMedica, Inc. (CALC)	$4.69M	N/A	N/A	N/A	N/A
Imunon, Inc. (IMNN)vs ›	$4.71M	N/A	1.64	1.64	1.64
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.72M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.55M	N/A	N/A	N/A	N/A
PharmaCyte Biotech, Inc. (PMCB)vs ›	$4.53M	N/A	1.25	1.25	1.25
Xenetic Biosciences, Inc. (XBIO)vs ›	$4.86M	N/A	N/A	N/A	N/A
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$4.97M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.40M	N/A	79.42	79.42	79.42
20/20 Biolabs Inc. (AIDX)vs ›	$4.32M	N/A	N/A	N/A	N/A
Lunai Bioworks Inc. (LNAI)vs ›	$5.12M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$1.49

÷

Forward EPS (Est.)

$-3.02

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

CALC PE Ratio Metrics

CALC Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics